急性缺血性卒中抗惊厥药一级与二级预防的决策分析
本研究用决策树模型比较三种抗惊厥预防策略对急性缺血性卒中患者质量调整生命年(QALY)的影响。四种临床情景下,长期一级预防的QALY均低于二级预防策略;仅在药物不良反应风险较高时,短期二级预防策略QALY最高。结论支持对卒中后未发生癫痫者停用预防性抗惊厥药并密切随访。
要点
- 长期一级预防在所有模拟情景中QALY最低,不优于二级预防策略。
- 仅发生卒中后癫痫时才持续抗惊厥预防的策略QALY最高。
- 急性缺血性卒中住院期间启用的预防性抗惊厥药应适时停用并随访。
核心结论
- 在全部四种模拟情景中,短期治疗且仅在卒中后出现癫痫时才持续抗惊厥预防的策略优于终身一级预防。
- 研究结果强调对急性缺血性卒中住院期间开始的抗惊厥预防需密切随访并及时停药。
研究设计与样本
- 研究采用决策树模型,评估三种抗惊厥预防策略对急性缺血性卒中患者质量调整生命年(QALY)的影响。
- 设置四种基础病例模拟常见临床情景,并在敏感性分析中调整参数与假设。
- 三种策略分别为:长期一级预防;早期癫痫发作后短期二级预防、若出现持续或晚期癫痫则终身预防;出现早期、晚期或持续癫痫后长期二级预防。
主要发现
- 情景1中策略2和策略3各获得7.17 QALY,而策略1仅6.91 QALY。
- 情景4中策略2和策略3获得2.85 QALY,策略1仅1.40 QALY。
- 在患者药物不良反应风险较高的情景中,策略2获得的QALY最多。
- 四种基础病例中,长期一级预防(策略1)相比二级预防策略均产生最少的QALY。
关键数值与推荐
- 情景1:40岁女性,晚期癫痫终生风险2%或11%,药物不良反应终生风险33%。
- 情景2:65岁男性,晚期癫痫终生风险6%或29%,药物不良反应风险60%。
- 情景3:50岁男性,晚期癫痫终生风险18%或65%,药物不良反应风险33%。
- 情景4:80岁女性,晚期癫痫终生风险29%或83%,药物不良反应风险80%。
临床怎么用
- 对急性缺血性卒中患者,不应常规启动长期抗惊厥一级预防。
- 住院期间启用的预防性抗惊厥药应在随访中评估并适时停用,仅在出现卒中后癫痫时考虑持续预防。
局限性
- 原文未报告模型参数来源、各策略具体药物及剂量、随访时限等细节。
- 结果为决策分析模型模拟,未经前瞻性临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We examined the impact of 3 anticonvulsant prophylaxis strategies on quality-adjusted life-years (QALYs) among patients with an incident acute ischemic stroke. METHODS: We created a decision tree to evaluate 3 strategies: (1) long-term primary prophylaxis; (2) short-term secondary prophylaxis after an early seizure with lifetime prophylaxis if persistent or late seizures (LSs) developed; and (3) long-term secondary prophylaxis if either early, late, or persistent seizures developed. The outcome was quality-adjusted life expectancy (QALY). We created 4 base cases to simulate common clinical scenarios: (1) female patient aged 40 years with a 2% or 11% lifetime risk of an LS and a 33% lifetime risk of an adverse drug reaction (ADR); (2) male patient aged 65 years with a 6% or 29% LS risk and 60% ADR risk; (3) male patient aged 50 years with an 18% or 65% LS risk and 33% ADR risk; and (4) female patient aged 80 years with a 29% or 83% LS risk and 80% ADR risk. In sensitivity analyses, we altered the parameters and assumptions. RESULTS: Across all 4 base cases, primary prophylaxis yielded the fewest QALYs when compared with secondary prophylaxis. For example, under scenario 1, strategies 2 and 3 resulted in 7.17 QALYs each, but strategy 1 yielded only 6.91 QALYs. Under scenario 4, strategies 2 and 3 yielded 2.85 QALYs compared with 1.40 QALYs for strategy 1. Under scenarios in which patients had higher ADR risks, strategy 2 led to the most QALYs. CONCLUSIONS: Short-term therapy with continued anticonvulsant prophylaxis only after postischemic stroke seizures arise dominates lifetime primary prophylaxis in all scenarios examined. Our findings reinforce the necessity of close follow-up and discontinuation of anticonvulsant seizure prophylaxis started during acute ischemic stroke hospitalization.
引用
- Jones FJS, Sanches PR, Smith JR, et al. Anticonvulsant Primary and Secondary Prophylaxis for Acute Ischemic Stroke Patients: A Decision Analysis. Stroke. 2021. PMID: 34126758. doi:10.1161/STROKEAHA.120.033299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。